Preparation Strategy and In Vitro Biological Performance Evaluation of Tannic Acid–Brushite In Situ Composite Bone Cement
Preparation Strategy and In Vitro Biological Performance Evaluation of Tannic Acid–Brushite In Situ Composite Bone Cement
Tannic acid–brushite in situ composite bone cement is a degradable calcium phosphate bone repair material in which polyphenolic molecules are introduced into the setting process of brushite bone cement, allowing tannic acid to participate simultaneously in crystal formation, particle bridging, and interfacial regulation during material construction.
Keywords: tannic acid; brushite; bone cement; in situ composite; calcium phosphate material; in vitro degradation; osteogenic evaluation; biocompatibility
1 Material Design Logic
1.1 Functional Positioning of Brushite Bone Cement
Brushite (CaHPO₄·2H₂O) bone cement is usually formed by the reaction between calcium phosphate powder and an acidic or weakly acidic liquid phase. It has characteristics such as injectability, moldability, low-temperature setting, and degradability. Its degradation rate is generally faster than that of hydroxyapatite-based bone cements, making it suitable for bone defect repair studies in which the material is expected to be gradually absorbed and replaced by new bone.
(1) Setting reaction
The setting of brushite bone cement depends on the calcium source, phosphate source, liquid-to-solid ratio, pH, and crystal nucleation process. Brushite crystals generated during the reaction interlock with one another and form the skeletal structure of the hardened cement.
(2) Material advantages
This material can set near body temperature and does not require high-temperature sintering, making it suitable for loading bioactive molecules or constructing in situ composite systems. As a calcium phosphate phase, brushite can participate in processes related to bone-like apatite formation through dissolution, ion exchange, and reprecipitation.
(3) Main limitations
Brushite bone cement often has limited early mechanical strength, insufficient anti-disintegration capability in wet environments, a relatively fast degradation rate, and a risk of local acidification. When used for composite modification, the balance among setting, strength, degradation, and cellular response should be considered simultaneously.
1.2 Material Significance of Introducing Tannic Acid
Tannic acid is a type of polyphenolic compound containing abundant phenolic hydroxyl groups. It can interact with calcium ions, proteins, and inorganic particle surfaces through coordination, hydrogen bonding, and multipoint adsorption. Introducing tannic acid into a brushite bone cement system can form organic-inorganic interactions during crystal growth and at particle interfaces.
(1) Crystal regulation
Tannic acid can coordinate with Ca²⁺ through phenolic hydroxyl groups, thereby affecting brushite nucleation and crystal growth. An appropriate amount of tannic acid may refine crystals and improve contact between particles, while excessive addition may delay setting or interfere with phase formation.
(2) Interfacial enhancement
Tannic acid can act as a multipoint binding molecule and form interfacial bridges between calcium phosphate particles, helping improve wet-state structural stability and anti-disintegration capability. Its effect depends on the addition level, dispersion method, and reaction rate of bone cement setting.
(3) Biological function regulation
Tannic acid has antioxidant properties, polyphenol-mediated interactions, and certain antibacterial potential. When used in bone cement composite systems, its release behavior, cytotoxicity threshold, and effects on osteogenesis-related cellular functions should be carefully evaluated to avoid inhibition of cell proliferation or mineralization caused by excessive concentration.
1.3 Key Features of In Situ Compositing
“In situ compositing” emphasizes that tannic acid participates in material formation during the bone cement setting process, rather than being applied by surface soaking after the cement has fully hardened. This strategy allows tannic acid to be distributed at crystal interfaces, within pore structures, and in particle connection regions, thereby influencing the overall material structure and release behavior.
Table 1 Design variables of tannic acid–brushite bone cement
Design Variable | Regulated Content | Possible Effects | Experimental Focus |
Tannic acid addition level | Tannic acid mass fraction or liquid-phase concentration | Setting time, crystal growth, release behavior, cellular response | Low, medium, and high dose gradients are recommended |
Liquid-to-solid ratio | Ratio of solid powder to liquid phase | Injectability, porosity, strength, degradation rate | Operability and forming strength should both be considered |
Calcium phosphate powder composition | Ratio of β-TCP, MCPM, DCPA, or related calcium phosphate salts | Brushite formation rate and residual phases | Phase composition should be confirmed by XRD |
Liquid-phase pH | Acidic/buffered liquid environment | Setting reaction, local acidification, cytocompatibility | Extract pH changes should be measured |
Mixing method | Tannic acid added into powder phase or liquid phase | Dispersion uniformity and interfacial interaction | Dissolution in the liquid phase is generally more favorable for uniform distribution |
Setting conditions | Temperature, humidity, mold size | Crystal growth, strength, and pore structure | Setting time and test conditions should be standardized |
2 Preparation Method
2.1 Powder and Liquid Phase Design
Tannic acid–brushite in situ composite bone cement is usually composed of calcium phosphate powder and a tannic acid-containing liquid phase. The solid phase may include β-tricalcium phosphate, monocalcium phosphate monohydrate, anhydrous dicalcium phosphate, or other calcium phosphate salt systems capable of forming brushite. The liquid phase may be water, dilute phosphate solution, citrate buffer system, or a tannic acid-containing aqueous system.
(1) Powder phase treatment
The particle size, drying state, and mixing uniformity of the calcium phosphate powder should be controlled. Smaller particle size can improve reactivity, but may shorten working time and increase liquid demand. Larger particle size can improve operability, but may lead to incomplete setting or increased residual phases.
(2) Method of adding tannic acid
Tannic acid can be pre-dissolved in the liquid phase so that it fully contacts calcium phosphate particles during mixing. If tannic acid is directly added to the powder phase in powder form, dispersion uniformity should be carefully controlled to avoid locally high concentrations that may affect setting.
(3) Control group setup
At minimum, a blank brushite bone cement group and composite groups with different tannic acid contents should be included. If the mechanism of tannic acid action is a key focus, a “post-soaking tannic acid group” can be added to distinguish the differences between in situ compositing and surface adsorption.
2.2 In Situ Composite Preparation Workflow
(1) Liquid phase preparation
Prepare tannic acid solutions at the designed concentrations. Adjust pH if necessary and store protected from light. Tannic acid is susceptible to oxidation and pH effects, so the liquid phase should preferably be freshly prepared and used immediately.
(2) Powder-liquid mixing
Rapidly mix the calcium phosphate powder phase with the tannic acid-containing liquid phase at a fixed liquid-to-solid ratio and stir until a homogeneous paste forms. Mixing time should be fixed to reduce setting differences among samples.
(3) Mold forming
Inject the bone cement paste into cylindrical or disc-shaped molds, then gently vibrate or level the surface to reduce large air bubbles. If injectability is evaluated, extrusion testing should be performed before molding.
(4) Setting and curing
Samples can be set at 37°C in a high-humidity environment or in a simulated body fluid-related environment. Setting time should be standardized for different test items, such as initial/final setting, 24 h mechanical testing, 7 d degradation, and long-term soaking evaluation.
(5) Demolding and post-treatment
After setting, demold the samples and record appearance, integrity, and surface defects. Samples for mechanical testing should have controlled dimensional accuracy. Samples for cell experiments should be sterilized, and it should be confirmed that the sterilization method does not significantly alter tannic acid structure or bone cement phase composition.
2.3 Key Points in Formulation Optimization
(1) Tannic acid content
Low-dose tannic acid is mainly used for interfacial regulation and introduction of release-related functionality. Medium doses may enhance particle connection and anti-disintegration performance. Excessive doses may delay setting, reduce early strength, or produce inhibitory effects on cells.
(2) Liquid-to-solid ratio
Increasing the liquid-to-solid ratio can improve flowability and injectability, but may also increase porosity and reduce compressive strength. An excessively low liquid-to-solid ratio may cause uneven mixing, difficult injection, and incomplete setting.
(3) Setting time
Bone cement should have a sufficient working window, but should not remain paste-like for too long. After tannic acid addition, changes in initial and final setting times should be measured to determine whether it interferes with brushite crystal formation.
3 Physicochemical Characterization
3.1 Setting and Handling Performance
Setting time, injectability, and anti-disintegration capability are fundamental indicators for evaluating whether in situ composite bone cement can form a stable material. Tannic acid may enhance wet-state stability through interfacial bridging, but it may also delay crystal nucleation by chelating Ca²⁺. Therefore, working window and setting integrity should be compared at different addition levels.
(1) Setting time
Initial and final setting times can be measured using a Vicat needle or penetration method. If the setting time of the tannic acid group is significantly prolonged, pH, phase formation, and residual powder should be further examined.
(2) Injectability
Injectability can be evaluated by syringe extrusion testing, including paste extrusion ratio and clogging behavior. A suitable system should allow continuous extrusion and avoid solid-liquid separation.
(3) Anti-disintegration capability
After initial setting, samples can be placed in PBS, Tris buffer, or simulated body fluid to observe whether edge collapse, particle shedding, or overall fracture occurs. Wet-environment integrity is particularly critical for brushite bone cement.
3.2 Phase and Structural Characterization
(1) XRD analysis
XRD is used to confirm whether brushite is formed as the main phase and to determine whether residual or transformed phases such as β-TCP, DCPA, MCPM, or hydroxyapatite are present. If brushite characteristic peaks weaken or residual phases increase after tannic acid addition, this suggests that tannic acid may affect the setting reaction.
(2) FTIR analysis
FTIR can simultaneously observe phosphate vibration peaks and tannic acid-related signals from phenolic hydroxyl groups and aromatic ring structures. Peak position or intensity changes can help determine interactions between tannic acid and calcium phosphate phases.
(3) SEM observation
SEM is used to observe crystal morphology, pore structure, and particle connection on fracture surfaces. An appropriate amount of tannic acid may alter the size and interlocking pattern of brushite crystals. High addition levels may inhibit crystal growth or lead to a loose structure.
(4) Porosity and water absorption
Porosity affects degradation, ion exchange, and cell infiltration, and also influences compressive strength. Pore structure changes can be evaluated using liquid displacement, mercury intrusion porosimetry, or microscopic image analysis.
3.3 Mechanical Properties
Compressive strength is a core indicator in the in vitro evaluation of bone cement. Brushite bone cement is usually used in non-high-load-bearing or local filling studies, so mechanical results should match the intended material application rather than solely pursuing the highest possible strength.
(1) Early strength
The 24 h compressive strength can reflect the early setting quality of the material. If tannic acid delays setting, early strength may decrease.
(2) Wet-state strength
Compressive strength after soaking is closer to material stability under body fluid-like environments. If tannic acid improves particle bridging or anti-disintegration capability, the wet-state strength retention rate may increase.
(3) Fracture morphology
The fracture surface after mechanical testing can be observed by SEM to determine whether failure originates from loose crystal interfaces, concentrated pores, or overall brittle fracture.
Table 2 Physicochemical evaluation indicators of tannic acid–brushite bone cement
Evaluation Item | Common Method | Main Observations | Interpretation Focus |
Setting time | Vicat needle/penetration method | Initial and final setting times | Determines whether tannic acid interferes with setting |
Injectability | Syringe extrusion test | Extrusion ratio and clogging behavior | Evaluates feasibility of simulated clinical handling |
Anti-disintegration capability | Soaking observation/mass retention | Fracture, particle shedding, integrity | Determines wet-environment stability |
Phase composition | XRD | Brushite peaks and residual phases | Determines whether the in situ reaction is sufficient |
Functional group interaction | FTIR | Phosphate peaks and phenolic hydroxyl peak changes | Determines organic-inorganic interactions |
Micromorphology | SEM | Crystal morphology, pores, particle connection | Evaluates structural compactness and interfacial status |
Compressive strength | Universal testing machine | Dry/wet strength | Determines mechanical support capability |
Porosity | Liquid displacement/image analysis | Total porosity and pore structure | Correlates degradation and mechanical results |
4 In Vitro Degradation and Release Performance Evaluation
4.1 Degradation Behavior
Brushite bone cement can undergo dissolution, redeposition, and ion exchange in aqueous environments. After tannic acid introduction, material degradation behavior may be jointly affected by crystal size, pore structure, and organic-inorganic interfacial interactions.
(1) Mass change
Samples can be immersed in PBS, Tris-HCl, or simulated body fluid, removed at defined time points, dried, and weighed. Increased mass loss generally indicates accelerated material degradation, but errors caused by surface powdering or sample fragmentation should also be excluded.
(2) pH change
The brushite system may cause local acidification. If pH fluctuation decreases after tannic acid addition, this may suggest that tannic acid regulates ion release or the buffer environment to some extent. If pH decreases significantly, potential inhibitory effects in cell experiments should be considered.
(3) Ca/P release
Detection of Ca²⁺ and phosphate concentrations in extracts can reflect material dissolution and calcium-phosphate exchange. Ca/P release should be interpreted together with XRD results, mass loss, and pH changes.
4.2 Tannic Acid Release Behavior
Tannic acid release determines its biological action window and also affects cytocompatibility and antioxidant/antibacterial performance. Excessively rapid release may cause local high-concentration stimulation, whereas excessively slow release may make functional regulation difficult to observe.
(1) Release curve
Tannic acid content in extracts can be measured by UV-Vis or HPLC to establish cumulative release curves. Recommended time points include 1 h, 6 h, 24 h, 3 d, 7 d, and 14 d.
(2) Initial burst release
If the release proportion within the first 24 h is too high, tannic acid may be mainly distributed on the surface or in weakly bound regions. In this case, the addition method should be optimized or the tannic acid content should be reduced.
(3) Sustained release
If the release curve gradually approaches a plateau, this indicates that tannic acid may form relatively stable interfacial interactions with the calcium phosphate phase. This result can be cross-validated with FTIR and XRD results after soaking.
4.3 In Vitro Mineralization Capacity
After immersion in simulated body fluid, the formation of bone-like apatite deposits on the material surface usually indicates a certain degree of in vitro mineralization activity. It should be noted that mineralization capacity alone is not equivalent to osteogenic performance and should be evaluated together with cell experiments.
(1) SBF immersion
Immerse samples in simulated body fluid and observe surface deposits at defined time points. The soaking solution should be replaced regularly or maintained at a stable volume according to the experimental design.
(2) Surface deposit observation
SEM can be used to observe plate-like, granular, or spherical deposit structures. EDS can detect changes in Ca/P elements, and XRD can determine whether apatite-related characteristic peaks appear.
(3) Effect of tannic acid
An appropriate amount of tannic acid may affect mineral deposition by chelating calcium ions and regulating the surface chemical environment. Excessive tannic acid content may also inhibit calcium phosphate deposition or alter deposit morphology.
5 In Vitro Biological Performance Evaluation
5.1 Cytocompatibility
Cellular evaluation of tannic acid–brushite bone cement should prioritize extract toxicity and direct contact responses on the material surface. Osteogenesis-related cells such as MC3T3-E1 cells, BMSCs, or osteoprogenitor cells are recommended.
(1) Extract experiment
Prepare extracts according to the ratio of material mass to extraction medium volume, and use them for CCK-8, Live/Dead staining, or cell morphology observation. Extracts can reflect the effects of material degradation products, ion release, and tannic acid release on cells.
(2) Direct contact experiment
Seed cells onto the sample surface and observe adhesion, spreading, and proliferation. If the surface is too loose or powdery, cell adhesion and microscopic observation may be affected.
(3) Concentration window determination
Low-dose tannic acid may improve the antioxidant microenvironment or surface interactions, while high-dose tannic acid may inhibit cell proliferation. Cell viability results should be analyzed in relation to the tannic acid release curve.
5.2 Osteogenesis-Related Evaluation
Osteogenic evaluation should cover early differentiation, intermediate matrix maturation, and late mineralization. A single indicator should not be used alone to judge the osteogenic-promoting effect of the material.
(1) ALP activity
ALP activity can be used to evaluate early osteogenic differentiation. If ALP increases in the tannic acid composite group while cell viability does not decrease, this suggests that the material may favor early osteogenic responses.
(2) Osteogenic gene expression
Genes such as RUNX2, ALP, COL1A1, OPN, and OCN can be detected. RUNX2 and ALP are more associated with early differentiation, whereas OCN and mineralized nodules are closer to a mature osteogenic phenotype.
(3) Mineralized nodules
Alizarin Red staining can be used to observe calcium deposition. Material blank controls should be included to avoid interference from calcium phosphate cement dissolution or surface deposits.
5.3 Antioxidant and Inflammation-Related Evaluation
The polyphenolic structure of tannic acid allows it to potentially participate in oxidative stress regulation. If the research objective involves an inflammatory microenvironment or bone defect repair microenvironment, antioxidant and inflammation-related evaluations should be included.
(1) ROS levels
Intracellular ROS levels can be detected under H₂O₂ stimulation or inflammatory models. If the tannic acid composite group reduces ROS while maintaining cell viability, its antioxidant effect has further research value.
(2) Macrophage response
RAW264.7 cells or bone marrow-derived macrophages can be used to evaluate inflammation-related phenotypes. Detection of TNF-α, IL-6, IL-10, Arg-1, and other indicators can help determine whether the material affects the direction of inflammatory responses.
(3) Hemolysis and blood compatibility
If the material may contact blood or the bone marrow environment, hemolysis rate and blood cell morphology can be evaluated. Because tannic acid has strong protein-binding ability, its potential effects on blood components should be considered.
Table 3 In vitro biological performance evaluation indicators
Evaluation Direction | Common Experiments | Main Indicators | Interpretation Focus |
Cell viability | CCK-8, Live/Dead | Cell survival rate, live/dead staining | Determines extract and material surface toxicity |
Cell adhesion | Fluorescent staining, SEM | Cell spreading, pseudopodia formation | Determines whether surface structure supports adhesion |
Early osteogenesis | ALP staining/activity assay | ALP expression and activity | Evaluates early differentiation capacity |
Osteogenic genes | qPCR/Western blot | RUNX2, ALP, COL1A1, OCN | Determines activation of osteogenic pathways |
Mineralization capacity | Alizarin Red staining | Calcium nodule formation | Evaluates late mineralization potential |
Antioxidant activity | ROS detection, antioxidant enzyme indicators | ROS, SOD, GSH, etc. | Determines functional release effects of tannic acid |
Inflammatory response | Macrophage model | TNF-α, IL-6, IL-10, Arg-1 | Evaluates effects on the immune microenvironment |
Blood compatibility | Hemolysis assay | Hemolysis rate, erythrocyte morphology | Determines blood-contact safety |
6 Result Interpretation and Formulation Screening
6.1 Characteristics of an Ideal Composite System
An ideal tannic acid–brushite in situ composite bone cement should simultaneously be operable, settable, structurally stable, and cell-friendly, rather than showing outstanding performance in only a single indicator.
(1) Controllable setting
After compositing, the setting time should remain within an operable range. If setting is significantly prolonged, tannic acid content should be reduced or liquid-phase pH and liquid-to-solid ratio should be adjusted.
(2) Defined phase composition
XRD should show brushite as the main product and avoid a large amount of unreacted residual phases. Excessive residual phases indicate insufficient in situ reaction.
(3) Wet-state stability
After soaking, samples should maintain their basic morphology and measurable strength. If samples rapidly powder, powder particle size, liquid-to-solid ratio, or organic phase content should be optimized.
(4) Cytocompatibility
In extract and direct contact experiments, cell viability should not be significantly lower than that of the blank control. If dose-dependent inhibition occurs, the safe addition range should be determined together with tannic acid release data.
6.2 Common Result Patterns
(1) Low-dose structural improvement
Low-dose tannic acid may improve the crystal interface and wet-state stability without significantly affecting setting. This result is usually suitable as a candidate formulation for subsequent osteogenic evaluation.
(2) Medium-dose functional enhancement
Medium-dose tannic acid may provide more obvious antioxidant or interfacial regulation effects, but it must be confirmed that early strength and cell proliferation are not sacrificed.
(3) High-dose inhibition of setting or cells
High-dose tannic acid may chelate excessive Ca²⁺, delay brushite formation, and cause cellular stress through release. If delayed setting, reduced strength, and decreased cell viability occur, such formulations should not be selected as preferred candidates.
7 Related Reagent and Material Selection
Table 4 Materials related to the preparation and characterization of tannic acid–brushite bone cement
Product/Material Name | CAS No. | Application Module | Application Positioning |
Tannic acid | In situ composite modification | Serves as a polyphenolic component involved in calcium phosphate crystal interfacial regulation and functional release | |
Brushite/dicalcium phosphate dihydrate | Bone cement phase/control material | Used for brushite phase identification, control materials, or construction of calcium phosphate systems | |
β-Tricalcium phosphate | Calcium phosphate powder | Used in the solid-phase reaction system of brushite bone cement | |
Monocalcium phosphate monohydrate | Phosphate powder | Used to react with calcium sources to form brushite bone cement | |
Anhydrous dicalcium phosphate | Calcium phosphate powder | Used for calcium phosphate bone cement formulation regulation and phase controls | |
Hydroxyapatite | Control material/mineralization material | Used for calcium phosphate material controls and mineralization-related research | |
Citric acid | Liquid-phase regulation | Used to regulate setting reaction, chelation environment, and liquid-phase pH | |
Alizarin Red S | Mineralization staining | Used to evaluate cellular mineralized nodules or calcium deposition on material surfaces | |
MTT | Cell viability detection | Used for evaluation of cell viability in material extracts or direct contact systems | |
DCFH-DA | ROS detection | Used to evaluate antioxidant performance of tannic acid composite systems |
Table 5 Reagents and consumables related to in vitro biological performance evaluation
Cat. No. | Product Name | Specification/Purity | Application Module | Application Positioning |
Cell Counting Kit-8 | BioReagent,for detection | Cell viability detection | Used for evaluating cell proliferation and cytocompatibility in material extract or direct contact systems | |
Solid instant dissolution Cell Counting Kit-8 |
| Cell viability detection | Used for cytotoxicity and proliferation trend analysis of bone cement extracts | |
Osteogenesis Assay Kit (Alizarin Red S) | for cell culture,for microscopy,BioReagent | Osteogenic mineralization staining | Used to observe mineralized nodule formation in osteoblasts and evaluate the mineralization-promoting ability of materials | |
Calcium Staining Solution (Alizarin Red S Method) | BioReagent,Biological Stain,for microscopy | Calcium deposition evaluation | Used for mineralized deposits on bone cement surfaces and osteoblast mineralization staining | |
Calcium Staining Solution (Modified Alizarin Red S Method) | BioReagent,for microscopy,Biological Stain | Calcium deposition evaluation | Used to observe calcium salt deposition on material surfaces or during cellular mineralization | |
Alizarin Red S Staining Solution (0.1%, pH4.2) | BioReagent,Biological Stain,for microscopy,0.1% | Calcium deposition staining | Used for low-concentration Alizarin Red S staining systems to observe cellular mineralization or calcium deposition on material surfaces | |
Alizarin Red S Staining Solution (0.2%, pH4.2) | BioReagent,Biological Stain,for microscopy,0.2% | Calcium deposition staining | Used for calcium nodule staining after osteogenic induction; a commonly used mineralization evaluation condition | |
Alizarin Red S Staining Solution (1%, pH4.2) | BioReagent,Biological Stain,for microscopy,1% | Calcium deposition staining | Used to observe weak mineralization deposition or calcium salt deposition on material surfaces | |
Alizarin red | indicator | Staining system preparation | Used for self-prepared Alizarin Red staining systems or method optimization | |
Alizarin red | ≥80%(HPLC) | Staining system preparation | Used for mineralization staining condition development and calcium deposition detection system preparation | |
RUNX2 Human Pre-designed siRNA Set A |
| Osteogenic mechanism validation | Used to validate the regulatory role of RUNX2 in material-induced osteogenic differentiation | |
Recombinant RUNX2 Antibody | Recombinant, ExactAb™, Validated, See COA | Osteogenic protein detection | Used to detect RUNX2 protein expression and evaluate early osteogenic transcriptional regulation | |
Recombinant RUNX1/RUNX2/RUNX3 Antibody | KD Validation | Osteogenic protein detection | Used for RUNX family-related protein detection and knockdown validation | |
Human Runt Related Transcription Factor 2 (RUNX2) ELISA Kit | BioReagent | RUNX2 quantitative detection | Used to measure RUNX2 levels in human-derived cells or samples | |
Rat Runt Related Transcription Factor 2 (RUNX2) ELISA Kit | BioReagent | RUNX2 quantitative detection | Used to detect RUNX2 in rat-derived cells or animal-related in vitro samples | |
Mouse Runt Related Transcription Factor 2 (RUNX2) ELISA Kit | BioReagent | RUNX2 quantitative detection | Used in studies involving mouse-derived osteoblasts such as MC3T3-E1 cells | |
COL1A1 Human Pre-designed siRNA Set A |
| Osteogenic matrix mechanism validation | Used to validate the role of COL1A1 in material-induced collagen matrix formation | |
Recombinant Human Pro-Collagen I alpha 1/COL1A1 Protein | Animal Free,Carrier Free,Bioactive,His Tag,≥90%(SDS-PAGE) | Collagen matrix research | Used for COL1A1-related method validation or osteogenic matrix research | |
Human Pro-Collagen alpha-1 Chain (Pro-col1a1) ELISA Kit | BioReagent | COL1A1 quantitative detection | Used to evaluate collagen matrix formation levels in human-derived osteoblasts | |
Mouse Collagen Type Ⅰ Alpha 1 (COL1A1) ELISA Kit | BioReagent | COL1A1 quantitative detection | Used to detect COL1A1 expression levels in mouse osteoblast models | |
Human Osteocalcin (BGP/OCN) ELISA Kit | BioReagent | Late osteogenesis detection | Used to evaluate osteogenic maturation and mineralization-related responses in human-derived cells | |
Rat Osteocalcin (BGP/OCN) ELISA Kit | BioReagent | Late osteogenesis detection | Used to detect OCN levels in rat-derived samples | |
Mouse Osteocalcin (BGP/OCN) ELISA Kit | BioReagent | Late osteogenesis detection | Used to evaluate OCN expression and mineralization maturation in mouse osteoblast models | |
Human Tumor Necrosis Factor Alpha (TNF-α) ELISA Kit | BioReagent | Inflammatory factor detection | Used to evaluate the effects of materials on inflammatory responses in human-derived cells | |
Rat Tumor Necrosis Factor Alpha (TNF-α) ELISA Kit | BioReagent | Inflammatory factor detection | Used to detect TNF-α in rat-derived cells or related in vitro samples | |
Mouse Tumor Necrosis Factor Alpha (TNF-α) ELISA Kit | BioReagent | Inflammatory factor detection | Used to detect TNF-α in mouse macrophage models such as RAW264.7 cells | |
Recombinant Human TNF-α Protein | Carrier Free,Bioactive,ActiBioPure™,High Performance,PBS Only,≥95%(SDS-PAGE) | Inflammatory model construction | Used to establish inflammatory stimulation conditions and evaluate cellular responses to materials in inflammatory microenvironments | |
Recombinant Mouse TNF-α Protein | Carrier Free,Bioactive,ActiBioPure™,High Performance,≥95%(SDS-PAGE),See COA | Inflammatory model construction | Used in inflammatory stimulation experiments involving mouse macrophages or osteogenesis-related cells | |
Human Interleukin 6 (IL-6) ELISA Kit | BioReagent | Inflammatory factor detection | Used to detect IL-6 release levels in human-derived cell systems | |
Rat Interleukin 6 (IL-6) ELISA Kit | BioReagent | Inflammatory factor detection | Used to detect IL-6 levels in rat-derived cells or samples | |
Mouse Interleukin 6 (IL-6) ELISA Kit | BioReagent | Inflammatory factor detection | Used to evaluate inflammatory responses in mouse macrophages or osteoblasts | |
IL-6 Antibody | ExactAb™, Validated, 1.0 mg/mL | Inflammatory protein detection | Used to detect IL-6 protein expression and support evaluation of material-induced inflammatory responses | |
Recombinant Human IL-6 Protein | Carrier Free,Bioactive,ActiBioPure™,Azide Free,High Performance,His Tag,PBS Only,≥95%(SDS-PAGE) | Inflammatory model construction | Used to establish IL-6-related inflammatory stimulation or positive control systems | |
Recombinant Mouse IL-6 Protein | Animal Free,Carrier Free,Bioactive,ActiBioPure™,Azide Free,High Performance,His Tag,≥95%(SDS-PAGE) | Inflammatory model construction | Used for inflammatory stimulation and pathway validation in mouse-derived cells | |
Human Interleukin 10 (IL-10) ELISA Kit | BioReagent | Anti-inflammatory factor detection | Used to evaluate whether materials induce or promote anti-inflammatory responses | |
Rat Interleukin 10 (IL-10) ELISA Kit | BioReagent | Anti-inflammatory factor detection | Used to detect IL-10 levels in rat-derived samples | |
Mouse Interleukin 10 (IL-10) ELISA Kit | BioReagent | Anti-inflammatory factor detection | Used to evaluate anti-inflammatory responses in mouse macrophage models | |
Recombinant IL-10 Antibody | ExactAb™, Validated, Recombinant, See COA | Anti-inflammatory protein detection | Used to detect IL-10 protein expression and support evaluation of material immunomodulatory effects | |
Recombinant Human IL-10 Protein | Animal Free,Carrier Free,Bioactive,ActiBioPure™,His Tag,PBS Only,≥90%(SDS-PAGE),See COA | Anti-inflammatory model construction | Used for IL-10-related positive controls or anti-inflammatory response validation | |
Recombinant Mouse IL-10 Protein | Animal Free,Carrier Free,Bioactive,ActiBioPure™,Azide Free,High Performance,His Tag,≥95%(SDS-PAGE) | Anti-inflammatory model construction | Used for anti-inflammatory stimulation and immunomodulatory validation in mouse-derived cells | |
Cell Staining Buffer | BioReagent, sterile-filtered | Cell phenotype analysis | Used for flow cytometric analysis of macrophage phenotypes, inflammatory responses, or cell status after material stimulation | |
Simulated Body Fluid SBF (1×) | BioReagent,sterile,1× | In vitro mineralization evaluation | Used to evaluate bone-like apatite deposition, mineralization capacity, and ion exchange behavior on material surfaces |
8 Frequently Asked Questions
8.1 Does adding more tannic acid necessarily improve bone cement performance?
No. Excessive tannic acid may chelate Ca²⁺ and interfere with brushite crystal formation, resulting in delayed setting, reduced early strength, or decreased cell viability. Low, medium, and high dose gradients are recommended to determine the safe addition range.
8.2 What is the difference between in situ compositing and surface soaking?
In situ compositing introduces tannic acid during the bone cement setting process, allowing it to participate in crystal nucleation, particle connection, and pore structure formation. Surface soaking mainly modifies the outer layer of the material. The two approaches may differ significantly in release behavior, interfacial binding, and long-term stability.
8.3 Why is it necessary to measure both XRD and FTIR?
XRD is used to determine whether the brushite crystalline phase is formed, while FTIR is used to observe changes in phosphate and tannic acid functional groups. Combining the two methods can explain both inorganic crystalline phases and organic-inorganic interactions.
8.4 Should PBS or Tris-HCl be selected for in vitro degradation experiments?
PBS is closer to a conventional physiological buffer system, but may undergo deposition or ion exchange with calcium phosphate materials. Tris-HCl is commonly used to evaluate dissolution and degradation of calcium phosphate materials. If the research goal is to comprehensively assess degradation behavior, both systems can be compared.
8.5 Is ALP detection alone sufficient for osteogenic evaluation?
No. ALP mainly reflects early osteogenic differentiation. It is recommended to combine RUNX2, COL1A1, OPN, OCN, and Alizarin Red mineralization staining to form a continuous evaluation covering early differentiation, matrix maturation, and late mineralization.
The evaluation of tannic acid–brushite in situ composite bone cement should focus on whether “setting is controllable, phase composition is defined, structure is stable, release is moderate, cells are compatible, and osteogenic responses are enhanced.” Only by jointly analyzing preparation parameters, physicochemical properties, and in vitro biological results can the reasonable addition range of tannic acid in brushite bone cement and the application potential of the material be determined.